WO2019004868A3 - Combination of a chondroprotective agent with an nsaid - Google Patents

Combination of a chondroprotective agent with an nsaid Download PDF

Info

Publication number
WO2019004868A3
WO2019004868A3 PCT/RU2018/000345 RU2018000345W WO2019004868A3 WO 2019004868 A3 WO2019004868 A3 WO 2019004868A3 RU 2018000345 W RU2018000345 W RU 2018000345W WO 2019004868 A3 WO2019004868 A3 WO 2019004868A3
Authority
WO
WIPO (PCT)
Prior art keywords
nsaid
combination
chondroprotective agent
osteoarthritis
chondroprotective
Prior art date
Application number
PCT/RU2018/000345
Other languages
French (fr)
Russian (ru)
Other versions
WO2019004868A2 (en
Inventor
Алексей Валерьевич ЧЕКАЛОВ
Original Assignee
Общество с ограниченной ответственностью "ФБК"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество с ограниченной ответственностью "ФБК" filed Critical Общество с ограниченной ответственностью "ФБК"
Publication of WO2019004868A2 publication Critical patent/WO2019004868A2/en
Publication of WO2019004868A3 publication Critical patent/WO2019004868A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Abstract

The invention relates to an oral agent containing diacerein, chondroitin and glucosamine, and to the use of same to treat osteoarthritis of the peripheral joints, intervertebral osteochondrosis, osteoarthritis and osteoporosis, periodontitis and/or for accelerating callus formation in fractures.
PCT/RU2018/000345 2017-06-30 2018-06-28 Combination of a chondroprotective agent with an nsaid WO2019004868A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2017123275A RU2742172C2 (en) 2017-06-30 2017-06-30 Combination of a chondroprotective agent with an nsaid
RU2017123275 2017-06-30

Publications (2)

Publication Number Publication Date
WO2019004868A2 WO2019004868A2 (en) 2019-01-03
WO2019004868A3 true WO2019004868A3 (en) 2019-02-07

Family

ID=64184153

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2018/000345 WO2019004868A2 (en) 2017-06-30 2018-06-28 Combination of a chondroprotective agent with an nsaid

Country Status (2)

Country Link
RU (1) RU2742172C2 (en)
WO (1) WO2019004868A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198695A1 (en) * 2003-04-02 2004-10-07 Anhu Li Joint-protecting beverages and/or foods and their preparations
WO2009065604A2 (en) * 2007-11-23 2009-05-28 Bayer Consumer Care Ag Pharmaceutical composition comprising glucosamine sulfate, chondroitine sulfate and ibuprofene
WO2010109256A1 (en) * 2009-03-23 2010-09-30 Carlo Ghisalberti Enhanced treatment of joint and connective tissue damage
EP2243478A1 (en) * 2007-09-26 2010-10-27 World Trade Import-Export, WTIE A.G. Pharmaceutical composition combining an antiarthritic agent and an interleukin-1 inhibiting agent, which can be used to control and treat osteoarthritis and related diseases
WO2013100882A2 (en) * 2011-12-27 2013-07-04 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Combinations of diacerein and non-steroidal inflammation drugs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2478376C1 (en) * 2011-11-24 2013-04-10 Общество С Ограниченной Ответственностью "Консорциум-Пик" Pharmaceutical composition based on vegetative dha for treating and preventing diseases of joints

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198695A1 (en) * 2003-04-02 2004-10-07 Anhu Li Joint-protecting beverages and/or foods and their preparations
EP2243478A1 (en) * 2007-09-26 2010-10-27 World Trade Import-Export, WTIE A.G. Pharmaceutical composition combining an antiarthritic agent and an interleukin-1 inhibiting agent, which can be used to control and treat osteoarthritis and related diseases
WO2009065604A2 (en) * 2007-11-23 2009-05-28 Bayer Consumer Care Ag Pharmaceutical composition comprising glucosamine sulfate, chondroitine sulfate and ibuprofene
WO2010109256A1 (en) * 2009-03-23 2010-09-30 Carlo Ghisalberti Enhanced treatment of joint and connective tissue damage
WO2013100882A2 (en) * 2011-12-27 2013-07-04 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Combinations of diacerein and non-steroidal inflammation drugs

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
E. TROFIMOV ET AL: "The effect of different treatments on the clinical course of knee osteoarthritis", OSTEOARTHRITIS AND CARTILAGE., vol. 26, 1 April 2018 (2018-04-01), GB, pages S306 - S307, XP055530990, ISSN: 1063-4584, DOI: 10.1016/j.joca.2018.02.617 *
R MIRUNALINI ET AL: "EFFICACY OF CHONDROITIN SULFATE WITH GLUCOSAMINE VERSUS DIACEREIN IN GRADE II AND III OSTEOARTHRITIS KNEE: A RANDOMIZED COMPARATIVE STUDY", ASIAN JOURNAL OF PHARMACEUTICAL AND CLINICAL RESEARCH : AJPCR, vol. 8, no. 4, 1 January 2015 (2015-01-01), IN, pages 244 - 246, XP055530976, ISSN: 0974-2441 *
STEINMEYER J ET AL: "Oral treatment options for degenerative joint disease-presence and future", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 58, no. 2, 20 May 2006 (2006-05-20), pages 168 - 211, XP024892181, ISSN: 0169-409X, [retrieved on 20060520], DOI: 10.1016/J.ADDR.2006.01.007 *

Also Published As

Publication number Publication date
RU2017123275A3 (en) 2019-01-09
RU2017123275A (en) 2019-01-09
WO2019004868A2 (en) 2019-01-03
RU2742172C2 (en) 2021-02-02

Similar Documents

Publication Publication Date Title
EP3556858A3 (en) Crispr/cas-related methods and compositions for treating cystic fibrosis
MX2016014807A (en) Alpha (1,2) fucosyltransferase syngenes for use in the production of fucosylated oligosaccharides.
EP3729258A4 (en) Amplifying, generating, or certifying randomness
MX2019010322A (en) Pharmaceutical compositions for combination therapy.
JOP20170055B1 (en) Composition for syrup containing allulose and food comprising the composition
AU2018280875A1 (en) Solid compositions for oral administration
MX2016012262A (en) Cenicriviroc for the treatment of fibrosis.
MY196308A (en) PTH Prodrugs
SG10201909805XA (en) Surface modified polymer compositions
MX2019000619A (en) Compounds and methods for modulation of smn2.
MX2019008917A (en) Pharmaceutical compositions for combination therapy.
WO2020127145A3 (en) Materials for electronic devices
MX2018005200A (en) Oral care products and methods comprising hydroxyapatite binding proteins.
EP3613402A4 (en) Curable composition for dental use, and method for producing same
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
AU2015352158A8 (en) Medicaments for slowing Parkinson's Disease
MX2022004024A (en) Methods and materials for treating neurotoxicity.
MX2016015413A (en) Calcium carbonate for rotogravure printing medium.
WO2019043176A3 (en) Hdac inhibitor in combination with antimetabolite agent for cancer therapy
EA202191631A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
WO2019078698A3 (en) Anti-msln antibody and pharmaceutical composition for cancer treatment comprising same
MX2017010277A (en) Cenicriviroc for the treatment of fibrosis.
MX2019005621A (en) Methods and compositions for treatment of cartilage damage and arthritis.
WO2019004868A3 (en) Combination of a chondroprotective agent with an nsaid
MX2018007838A (en) Mucin coated silica for bacterial aggregation.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 17.06.2020)

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18799879

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 18799879

Country of ref document: EP

Kind code of ref document: A2